April 18th 2024
A study presented at the Society for Healthcare Epidemiology of America (SHEA) conference assesses the link between antibiotic use and C difficile infection in Tennessee.
Fecal Transplant Benefits C diff Patients Coinfected With COVID-19
February 4th 2023Treating Clostridioides difficile infection is complicated in patients coinfected with COVID-19. However, a new study suggests a significant benefit of fecal microbiota transplant (FMT) in these coinfected patients.
Read More
Looking at Reimbursement Economics of CDI in Healthcare Systems
January 11th 2023Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.
Watch
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization
December 7th 2022Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.
Watch
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)
October 5th 2022Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
Watch
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
September 22nd 2022The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
Read More